The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

IV.a

Bronchospasm - Wheezing - Asthma

Publications

Alas R, Williams MT, Yamin G, Rofoogaran M

Chronic cough and an atypical pattern of peripheral pulmonary opacities: A case report secondary to suspected drug onset.

The Journal of asthma : official journal of the Association for the Care of Asthma 2018 01;55;106-110 — 2018 01 — 106-110

M?rgineanu I, Cri?an R, Mih?escu T

Asthma-like symptoms in a patient with rheumatoid arthritis and Adalimumab treatment.

Pneumologia (Bucharest, Romania) 2015 Oct-Dec;64;28-30 — 2015 Oct-Dec — 28-30

Guilleminault L, Carré P, Beau-Salinas F, Taillé C, Dieudé P, Crestani B, Diot P, Marchand-Adam S

Asthma unmasked with tumor necrosis factor-?-blocking drugs.

Chest 2011 Oct;140;1068-1071 — 2011 Oct — 1068-1071

Dubey S, Kerrigan N, Mills K, Scott DG

Bronchospasm associated with anti-TNF treatment.

Clinical rheumatology 2009 Aug;28;989-92 — 2009 Aug — 989-92

Janssen R, Krivokuca I, Kruize AA, Koenderman L, Lammers JW

Adalimumab-induced bronchospasm: not a class effect.

Thorax 2008 May;63;472-3 — 2008 May — 472-3